Optellum Company

Optellum develops an imaging biomarker for smart lung cancer detection. OptellumвАЩs vision is to redefine cancer care, by enabling every clinician, in every hospital, to manage their patients in the optimal way. They do that by providing end-end IT platform for personalized early diagnosis and therapy, based on the collective experience of thousands of doctors pooled by machine learning applied to vast patient datasets. Their first suite of products targets management of patients at high risk of developing lung cancer вАУ the worldвАЩs deadliest and commonest cancer вАУ from early diagnosis through to treatment. Optellum comprises a team of award-winning medical imaging software, AI, and clinical experts who met at OxfordвАЩs world-renowned computer vision lab. Between us, they have track records of bringing innovation to market through over 10 start-up companies, resulting already in 5 trade-sales and one IPO. They are backed by an Advisory Board comprising world-leading clinicians and experts in deep learning


Connections from

Funding Status: Early Stage Venture
Headquarters: Oxford, Oxfordshire, United Kingdom
Total Funding: 15297959
Last Funding Date: 2022-09-27
Investors Number: 9
Founded Date: 2016-01-01
Technology: Medical BioTech
Industry: Imaging
Last Funding Type: Series A
Employee Number: 45200